Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as fatty liver disease, affects about one in three adults worldwide and poses major health risks, not only for the liver but…
Acknowledgement: Patient Worthy is proud to share this article from our friends at the Fatty Liver Foundation. As a patient, what I really want to understand is how damaged is…
According to a recent article from JournalFeed, the relationship between type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly coming to the forefront of clinical care. MASLD,…
The results released from the Phase III ESSENCE clinical trial, and recently published by Medical Xpress and in the NEJM, found that the drug semaglutide is effective in the treatment…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
